Left Atrial Strain as a Potential Parameter to Detect Cancer Therapy-Related Cardiac Dysfunction: An Editorial Commentary and Systematic Review

Currently, and as it has been for many years, left ventricular (LV) ejection fraction (LVEF) remains the most important and clinically relevant parameter for clinical decision-making and for detecting cancer therapyrelated cardiac dysfunction (CTRCD). 1 In this respect, according to the 2022 European Society of Cardiology (ESC) Guidelines on CTRCD, 1 in any patient with an LVEF < 50% before starting cancer therapy, the risk/benefit of cardiotoxic anticancer treatment, particularly with anthracyclines, should be evaluated, and cardioprotective strategies should be considered. 1 Likewise, in any patient with an induced LVEF < 50% after anthracycline therapy, the use of this anticancer therapy should be interrupted.